Hemant Surgical Acquires Majority Stake in Lifesenz Cancer Research Labs to Boost Precision Oncology Portfolio
Hemant Surgical Industries Limited has completed the strategic acquisition of a majority stake in Lifesenz Cancer Research Labs Private Limited, integrating precision oncology and personalized cancer treatment solutions into its specialized healthcare portfolio. The acquisition was finalized for an amount of Rs. 19.98 Crores, granting Hemant Surgical control over 66.66% of Lifesenz, effective from June 01, 2026.Hemant Surgical Industries Limited, an established manufacturer and marketer of medical disposable equipment and pharmaceutical products in India, is expanding its operations into the high-growth segment of precision medicine through this strategic move. Lifesenz focuses on advanced ex-vivo chemo-sensitivity analysis using patient derived 3D cancer cell models. This capability allows oncologists to evaluate potential treatment options based on a patient's own cancer cells before therapy begins, supporting informed clinical decision making in oncology care.
The acquisition aligns with the company’s long term strategy to participate beyond traditional healthcare distribution and into emerging advanced diagnostics. By integrating Lifesenz’s scientific capabilities with Hemant Surgical’s existing market reach, the company aims to enhance its portfolio with differentiated healthcare solutions and expand its participation in specialized oncology markets.
Hemant Surgical noted that the integration of Lifesenz's scientific focus with its established ecosystem is expected to strengthen relationships with hospitals and clinicians while creating a platform for future expansion in precision medicine across India.
The company maintains a long term strategic viewpoint regarding this investment, acknowledging that Lifesenz is currently undergoing growth and development phases involving investments in research, technology, infrastructure, and market expansion. Management has determined that the acquisition offers compelling strategic advantages immediately rather than near term profitability. To facilitate future revenue growth and shareholder value creation, Hemant Surgical intends to focus on scaling operational capabilities, expanding patient adoption, strengthening clinical collaborations, and increasing commercialization opportunities.
Commenting on the strategic importance of the purchase, Mr. Hanskumar Shamji Shah, Managing Director of Hemant Surgical Industries Limited stated that precision oncology represents an area of significant global relevance. He added that by combining Lifesenz’s scientific expertise with Hemant Surgical's established healthcare platform, the company is building a foundation for long term growth and improved patient care outcomes in this transformative segment of healthcare.
Stock Price Movement
As of 13:40, Hemant Surgical Industries Ltd shares are ticking up at ₹365.50, gaining 1.39%. The stock has been volatile today, moving between an intraday low of ₹362.00 and a high of ₹370.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.